Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess whether SARS-CoV-2-neutralising mAbs are effective and safe for treating patients with COVID-19 in comparison to an active comparator, placebo or no intervention, and to maintain the currency of the evidence, using a living systematic review approach. A secondary objective is to track newly developing SARS-CoV-2-targeting mAbs from first tests in humans onwards.
Bibliographical noteFunding Information:
The research was supported by NHS Blood and Transplant and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
NK: is funded by the Federal Ministry of Education and Research, Germany (NaFoUniMedCovid19, funding number: 01KX2021; part of the project "COVIM", which was paid to the institution).
The research was part of a project supported by the German Federal Ministry of Education and Research (NaFoUniMedCovid19, funding number: 01KX2021; part of the project "COVIM"). The contents of this document reflect only the authors' views and the German Ministry is not responsible for any use that may be made of the information it contains.
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.